

1 November 2022

Use of Biologic Medicines in Gastroenterology

I have a Freedom of Information query regarding the use of Biologic medicines in Gastroenterology. Could you please answer the following two questions?

1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 84
- Adalimumab Biosimilar 350
- Filgotinib 0
- Golimumab 10
- Infliximab – Remicade 84
- Infliximab Biosimilar 260
- Ozanimod 0
- Tofacitinib 4
- Ustekinumab 115
- Vedolizumab 235

2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab – Humira 14
- Adalimumab Biosimilar 110
- Filgotinib 0
- Golimumab 10
- Infliximab – Remicade 16
- Infliximab Biosimilar 95
- Ozanimod 0
- Tofacitinib 4
- Ustekinumab 1
- Vedolizumab 105